Should we consider calcimimetics as a therapeutic option for nephrotic syndrome?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 35597590.
- Also identified by DOI 10.1016/j.kint.2022.04.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Calcimimetics allosterically increase the calcium ion sensitivity of the calcium-sensing receptor (CaSR). Using a CaSR knockdown in podocytes and a podocyte-specific CaSR knockout in mice, Mühlig et al. uncovered a stabilizing role for actin cytoskeleton and cell adhesion. Short-term alleviation of albuminuria and proteinuria was observed in 4 children treated with cinacalcet. Here we discuss the potential mechanisms whereby CaSR displays a favorable effect in podocytes and the context in which calcimimetics may alleviate nephrotic syndrome.
Medical subject headings
- Nephrotic Syndrome
- Podocytes